Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.58 |
| ▸ | HTR2C | P28335 | 5/20 | 0.54 |
| ▸ | DRD2 | P14416 | 5/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | CLEC4M | Q9H2X3 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9373707 | 0.75 | HTR7 (0.69) | HTR1AHTR2CDRD2HTR2AMEN1 | |
| SCHEMBL13648739 | 0.73 | DRD2 (0.65) | HTR1AHTR2CDRD2HTR2ADRD3 | |
| SCHEMBL10737253 | 0.73 | HTR2C (0.53) | HTR1AHTR2CDRD2MEN1KMT2A | |
| SCHEMBL6193449 | 0.73 | HTR1A (0.55) | HTR1AHTR2CDRD2HTR2AMEN1 | |
| Ammonia Solution, Strong SCHEMBL2320933 | 0.72 | DRD2 (0.64) | HTR1AHTR2CDRD2HTR2ADRD3 | |
| SCHEMBL10735159 | 0.72 | HTR7 (0.55) | HTR1ADRD2MEN1KMT2AHTR7 | |
| SCHEMBL27806422 | 0.71 | ADRA1A (0.76) | HTR1ADRD2DRD3DRD4ADRA1D | |
| SCHEMBL9414716 | 0.71 | CYP3A4 (0.72) | HTR1AHTR2CDRD2HTR2AMEN1 | |
| SCHEMBL1779199 | 0.71 | DRD2 (0.62) | HTR1AHTR2CDRD2HTR2ACYP2C19 | |
| SCHEMBL20502842 | 0.70 | HTR7 (0.55) | HTR1ADRD2HTR7DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034872-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2015-05-19 | — | — | US | disclosed |
| US-20140107128-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. | 2014-04-17 | — | — | US | disclosed |
| EP-2233472-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S A (LU) | 2014-01-15 | — | — | EP | disclosed |
| US-8614319-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2013-12-24 | — | — | US | disclosed |
| US-20130072479-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2013-03-21 | — | — | US | disclosed |
| US-8349850-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2013-01-08 | — | — | US | disclosed |
| EP-2233472-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | Atir Holding S.A. (LU) | 2010-09-29 | — | — | EP | disclosed |
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | ATIR HOLDING S.A. (LU) | 2010-02-04 | — | — | US | disclosed |
| EP-2010505-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | Atir Holding S.A. (LU) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007110868-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | PDE5A, PDE3B, PDE3A | HTR1A 261/4885HTR2C 186/4885DRD2 33/4885 |
| US-20140107128-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | PDE5A, PDE3B, PDE3A | HTR1A 440/4885HTR2C 465/4885DRD2 32/4885 |
| US-20130072479-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | PDE5A, PDE3B, PDE3A | HTR1A 261/4885HTR2C 186/4885DRD2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.